Skip to main content

glycopyrronium

Generic: GLYCOPYRRONIUM TOSYLATE·Brand: Bevespi, Breztri, Cuvposa, Dartisla, GLYCOPYRRONIUM TOSYLATE, Glycate, Glyrx, Lonhala, Prevduo, QBREXZA, Qbrexza, Robinul

glycopyrronium: developed by 1 company · 2 clinical trials tracked · 1 FDA decision.

glycopyrronium evidence translation

What we can confirm

1 FDA record · 2 tracked trials

What it means

Source-backed records connect glycopyrronium to DERM; that link alone does not prove the drug works.

What to watch

Watch active trials and any change in FDA or trial status.
BioSniper AIPage evidence connected

Prepared research question

How could glycopyrronium → DERM affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence2 indications · 1 study sponsors

Related indications

Primary axillary hyperhidrosisChronic Obstructive Pulmonary Disease
Development Pipeline (1)
CompanyPhase
Journey Medical Corp (DERM)
Primary axillary hyperhidrosis
Approved
Clinical Trials (2)

A Randomised, Double-blind, Multi-centre, Placebo-controlled, Crossover Study to Assess the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler on Cardiac and Lung Function in Participants With Chronic Obstructive Pulmonary Disease and Hyperinflation

NCT07073950·Phase 4·AZN
Recruiting

Primary endpoint: Change from baseline in left ventricular end diastolic volume indexed by body surface area (LVEDVi) measured by magnetic resonance imaging (MRI)

InterventionalRandomizeddouble56 targetStarted 2025-11Completion 2027-057 sites · Germany, United KingdomAstraZeneca

The Effect of Inhaled Corticosteroids (ICS) Adjunct Therapy on Pulmonary Vascular Endothelial Function in Chronic Obstructive Pulmonary Disease (COPD): Comparison of Two Standard Treatments (NCT05607719

NCT05607719·Phase 2
Active, not recruiting

Primary endpoint: Albuterol induced percent change in pulmonary vascular resistance (PVR)

InterventionalRandomizedtriple30 targetStarted 2023-04Completion 2026-071 site · United StatesUniversity of Miami
FDA Decisions1 records
Approval1 INDICATIONS AND USAGE Qbrexza is indicated for topical treatment of primary axillary hyperhidrosis in adult and pediatric patients 9 years of age and older. Qbrexza is an anticholinergic indicated for topical treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older ( 1 ).(DERM)FDA ↗
NDA210361Type 3 - New Dosage FormStandardTopicalCloth

Frequently asked questions

Who is developing glycopyrronium?

glycopyrronium is being developed by Journey Medical Corp.

How many clinical trials involve glycopyrronium?

BioSniper tracks 2 clinical trials involving glycopyrronium.

What is glycopyrronium's latest FDA decision?

The most recent tracked FDA decision for glycopyrronium is Approval for 1 INDICATIONS AND USAGE Qbrexza is indicated for topical treatment of primary axillary hyperhidrosis in adult and pediatric patients 9 years of age and older. Qbrexza is an anticholinergic indicated for topical treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older ( 1 )., dated June 28, 2018.